CASI Pharmaceuticals is an innovative biopharmaceutical company developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases. self-described.

CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. | 1,104 followers on LinkedIn. Bringing life-changing therapeutics to China and the world. | CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which all of our China operations are conducted.

CASI Pharmaceuticals, Inc.

Viewport Meta

IPhone / Mobile Compatible

Apple Mobile Web Clips Icon

HSTS

Content Delivery Network

Font Awesome

nginx

Apple Mobile Web App Capable

CloudFront

Common Name Invalid

Business Management

Larry Zhang

VP, Global Financial Controller

Amanda Cui

Senior Vice President

Jim Goldschmidt

Program Director

Alexa Harrod

Director, Supply and Manufacturing

Jin Xu

General Manager Commercial

Zhang Fuqiang

Network Security Manager

Brandi Rice

Caitlin Martin

Cathy Jones

Emily Martin

John W Holaday

co-founder

Alexander A. Zukiwski

James Goldschmidt

Senior Vice President of Business Development

Alexander Zukiwski

Executive Vice President and Chief Medical Officer

Dan Lang

CFO and SVP

Elisabeth Uible

Corporate Communications

Medical Public Companies With Less Than $50M in Revenue

University of California, San Francisco Alumni Founded Companies

Pharmaceutical Public Companies With Less Than $50M in Revenue

United States Public Companies With Less Than $500M in Revenue

CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.

Foresite Capital

Venrock Healthcare Capital Partners

Post-IPO Equity - CASI Pharmaceuticals

IDG Capital

GE Healthcare

Post-IPO Debt - CASI Pharmaceuticals

Rockville

Maryland

United States

North America

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Casi Pharmaceuticals files to sell 3M ordinary shares for holders

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Casi Pharmaceuticals management to meet virtually with Jefferies

CASI Pharmaceuticals jumps after receiving acquisition proposal for entire China business

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

India

Asia

France

Europe

Pakistan

HTML5

Google Analytics

Modernizr

Microsoft Outlook

jQuery

F5 NGINX

Starfield SSL

Google Fonts

Office 365

Apache Server

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 21, 2024 11:58 AM	1af432e6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 21, 2024 11:58 AM	8c5686e5
crunchbase trigger	general	Nov 21, 2024 11:58 AM	276e4d3a
crunchbase profile	general	Nov 21, 2024 4:31 PM	d651d4ee
li profile	general	Nov 21, 2024 11:58 AM	db5636c5
translate crunchbase fundingrounds	general	Nov 21, 2024 5:50 PM	72090817
peers	general	Nov 21, 2024 11:58 AM	62a8ac2d
news basic	general	Nov 21, 2024 11:58 AM	27eb7099
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CASIPHARMACEUTICALS

CASI Pharmaceuticals

Last Close

5.29

22/11 21:00

Market Cap

87.38M

Beta: -

Volume Today

16.02K

Avg: -